GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference
November 13 2020 - 08:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in a virtual fireside chat at
the Stifel 2020 Virtual Healthcare Conference on Monday, November
16, 2020, at 2:00 p.m. Eastern Time.
The fireside chat will be webcast live from GBT’s website at
www.gbt.com in the Investors section. A replay of the webcast will
be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a P-selectin
inhibitor in development to address pain crises associated with the
disease, and GBT021601, the company’s next generation hemoglobin S
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next wave of treatments
for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact Information:Steven Immergut (investors
and media)650-410-3258simmergut@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2023 to Mar 2024